Figure 3From: Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacementMeta analysis on the relative risk VTEs in unfractionated heparin controlled trials evaluating enoxaparin or dalteparin in THR patients. The pooled VTE relative risk was not significantly different between LMWHs (dalteparin or enoxaparin) vs. UH; p = 0.12. Test for heterogeneity: Chi2 = 7.42, df = 6, p = 0.28, I2 = 19.1%Back to article page